Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Quality Index
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Quality Index of 2.22x as of March 2026. Operating cash flow of $50.20 Million exceeds net income of $22.59 Million, indicating high earnings quality where cash backs reported profits. Explore Kiniksa Pharmaceuticals Ltd cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Kiniksa Pharmaceuticals Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Kiniksa Pharmaceuticals Ltd (2022–2023)
Year-by-year earnings quality comparison for Kiniksa Pharmaceuticals Ltd. For live market cap and the full company financial profile, see market cap of Kiniksa Pharmaceuticals Ltd.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.94x | $13.30 Million | $14.08 Million | ▲ +2882.1% |
| 2022 | 0.03x | $5.81 Million | $183.36 Million | — |